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Abstract
Background: Probiotics have rarely been studied in young healthy infants from low-income countries. This phase I
study investigated the safety and acceptability of two probiotics in Bangladesh.
Methods: Healthy infants aged four to twelve weeks from urban slums in Bangladesh were randomized to one of
three different intervention dosing arms (daily, weekly, biweekly – once every two weeks) of Lactobacillus reuteri
DSM 17938 and Bifidobacterium longum subspecies infantis 35624 over one month or to a fourth arm that received
no probiotics. All subjects were followed for two additional months. Reported gastrointestinal and respiratory
symptoms as well as breastfeeding rates, hospitalizations, differential withdrawals, and caretakers’ perception of
probiotic use were compared among arms.
Results: In total, 160 infants were randomized (40 to each arm) with 137 (Daily n = 35, Weekly n = 35, Biweekly
n = 35, Control n = 32) followed up for a median of twelve weeks; 113 completed the study. Illness and
breastfeeding rates were similar across all arms. Ten hospitalizations unrelated to probiotic use occurred. Forty
eight percent of the caretakers of infants in intervention arms believed that probiotics improved their baby’s health.
Conclusions: These two commonly used probiotics appeared safe and well-accepted by Bangladeshi families.
Trial registration: ClinicalTrials.gov NCT01899378. Registered July 10, 2013.
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Background
Probiotics are living microbial organisms that when ad-
ministered in adequate amounts confer health benefits
to the host [1]. Although a number of probiotic strains
have been shown to be safe and to improve health by a
variety of mechanisms [2, 3], few studies have assessed
probiotics in healthy young infants in low-income coun-
tries. Gut microbiota of children in low-income countries
differ from those in wealthier nations [4]. Gastrointestinal
pathogens and diarrheal disease are more common in
children in low-income countries, as is environmental en-
teropathy, a condition of increased intestinal permeability
and decreased nutrient absorption [5]. We and others
speculate that probiotics could modify gut microbiota, en-
hance gut immunity, and decrease gastrointestinal disease
risk, especially if administered early in life [6]. Further-
more, probiotics administered early in life may have the
greatest potential to achieve long-term colonization and
immunologic benefits, before infants have begun to re-
ceive complementary foods and their microbiota shift to a
more mature assemblage. However, it is possible that
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probiotics may induce adverse events in young infants
with dysbiosis, reduced intestinal integrity, and decreased
immunity [7, 8]. Therefore, determining safety in this in-
fant population is crucial.
The choice of probiotics in this study was based on a
literature review and strong safety data in infants. Lacto-
bacillus reuteri DSM 17938 (parent strain L. reuteri
ATCC 55730) [9] has been safely used in infants [10]
and adults in the US and Europe [11] and recently in
adults in the Peruvian Amazon [12] and has been re-
ported to prevent or reduce diarrhea and gastrointestinal
and respiratory infections [13–15], reduce pathogen
colonization and alter microbiota composition [16, 17],
reduce infant colic and crying time [18–20], suppress
Helicobacter pylori and gastric symptoms [21], relieve
constipation [22], control reflux and abdominal pain
[23], and improve infant weight gain [24]. Bifidobacter-
ium longum subspecies infantis is commonly found in
both breast milk [25] and healthy infant stools [4] and is
generally recognized as safe [26].
With the ultimate goal of evaluating the efficacy of
probiotics to improve health in children in Bangladesh,
the objectives of this report are to assess the safety and
acceptability of three different regimens of Lactobacillus
reuteri DSM 17938 and Bifidobacterium longum subspe-




Infants were recruited from three vaccination clinics
near the International Center for Diarrheal Disease Re-
search, Bangladesh (ICDDR,B) in Dhaka between Octo-
ber 2013 and April 2014. Inclusion criteria were: a) four
to twelve weeks of age; b) no birth defects, history of
hospitalization, or ongoing acute or chronic illness; c) no
current antibiotic or probiotic use; d) weight within
three standard deviations of the norm; and e) local resi-
dence for next four months. To select for infants who
were more likely to be affected by environmental enter-
opathy, gastrointestinal infections, malnutrition, and
stunting, children from lower socioeconomic status
communities from households that shared a kitchen,
water source, latrine, or courtyard with at least one
other household were recruited. No restrictions on the
diet of participating infants were made during the study.
Parents or guardians provided written informed consent.
The study was approved by the institutional review
boards at both ICCDR,B (Protocol ID 13022) and Stan-
ford University (Protocol ID 25487) and was registered
on ClinicalTrials.gov (NCT01899378).
For the primary outcome of this study, proportion of
days with symptoms, to detect a difference in change of
0.15 between the two groups with a sigma of 0.18 and
an alpha of 0.05 and greater than 80 % power, 25 infants
were needed per group. Twenty five infants in each
group would allow detection of almost a two-fold differ-
ence (74 % vs. 35 %) between arms with 80 % power for
dichotomous variables such as breastfeeding rates. Be-
cause the study population was transient, high levels of
drop-out and loss to follow-up were expected. A similar
study in this population had a 38 % drop-out rate; there-
fore 40 infants were enrolled per arm in order achieve a
final sample size of at least 25 infants per arm [27].
Study design
The study design was multi-arm parallel where infants
were randomized in equal numbers to one of four arms
– a control arm (observation only) or to one of three
intervention arms of L. reuteri DSM 17938 (108 colony
forming units (CFU)) and B. longum subspecies infantis
35624 (109 CFU): daily dosing (29 doses overall), weekly
dosing (five doses), or every two week dosing (three
doses). Block randomization using a computerized ran-
dom number generator and block sizes of twenty was
used to account for seasonal differences. The primary re-
searcher generated the sequence and the field research
officer in charge of coordinating enrollment was blinded
to block sizes. Enrollment was conducted by multiple
field team members simultaneously. After screening and
obtaining consent for an infant, the field team member
contacted the field research officer for the next enroll-
ment identification number to be assigned. Post-
intervention follow-up occurred for two months (Fig. 1).
Data collection ended in July 2014 when the final par-
ticipating infant completed follow-up.
Fig. 1 Study design and sampling scheme
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Intervention
L. reuteri DSM 17938 (BioGaia, Sweden), in liquid drops,
was stored and transported to the field at 4–8 °C; each dose
was five drops. B. longum subspecies infantis 35624 (Proc-
tor and Gamble), a powder-containing capsule, was stored
and transported at ambient temperature. Immediately be-
fore administration the capsule was opened and the power
was mixed with < 500ul sterile water to create a liquid sus-
pension. Both probiotics were fed to infants by study staff
using sterile Pasteur pipets in participating infants’ homes.
Mothers were encouraged to breastfeed infants after each
probiotic administration to ensure that the probiotic was
swallowed. Infants were monitored by study staff for at least
30 min for immediate adverse reactions.
Data collection
Demographic and socioeconomic data were collected at
enrollment. Health information, including gastrointes-
tinal and respiratory symptoms as well as breastfeeding
practices, was collected from caregivers on each of the
seven days after the first and last probiotic doses and
weekly at all other times covering the interval since last
visit (Fig. 1). Exclusive breastfeeding was defined as the
reported receipt of only breast milk in the prior 24 h
[28]. At the end of the study, data were collected regard-
ing the caretakers’ perceptions of probiotics. All survey
data were collected electronically by study staff with
Open Data Kit (ODK) software (https://opendatakit.org/)
on portable tablets [29]. All infant hospitalizations were
immediately reported to and reviewed by the Data Safety
Monitoring Board (DSMB) at the ICCDR,B. Infants who
were hospitalized continued in the study after they were
released from the hospital unless they were withdrawn
from the study by their parents.
Statistical analysis
Intent-to-treat analysis of those who initiated the study
after randomization was performed; infants for whom
no follow-up data were available were not included.
Baseline demographic characteristics of infants and their
households were compared among arms using the
Kruskal-Wallis or chi-squared test. The primary out-
comes of gastrointestinal and respiratory symptoms per
infant (days with symptoms/total follow-up days) were
compared with the Kruskal-Wallis test and a test for
trend. Withdrawals, symptoms and monthly household
income within and between the arms were compared
using two-way ANOVA or chi-squared tests. Rates of ex-
clusive breastfeeding among arms were compared using
difference in proportion or chi-squared tests.
There were concerns by the ICDDR,B review commit-
tee that oral administration of probiotics could affect
breastfeeding rates. Therefore, a stopping rule was im-
plemented that if probiotics caused a reduction in
breastfeeding, the trial would be stopped. At midline, in-
terim analysis on breastfeeding data only was conducted
and reported to the Data Safety Monitoring Board.
Results
A total of 613 infants were screened; 275 were considered
eligible (45 %) and 160 were enrolled (26 %), with 40 ran-
domized to each study arm (Fig. 2). The most common
reasons for ineligibility were moving outside of Dhaka
(n = 97) or the infant was not currently healthy (n = 122).
A total of 23 infants withdrew or were lost to follow-up
after baseline data collection but before the intervention
began, leaving 137 infants (86 %) contributing post-
intervention data with a median follow-up of twelve weeks.
These 137 infants were similar across arms (Table 1)
Fig. 2 Flow-chart of study screening, enrollment, and retention
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although monthly household income was slightly lower
in the weekly and daily treatment arms (p = 0.04). Of
the 137 babies who contributed post-intervention
data, 113 infants (82 %) completed the three months
post-intervention of the study.
Withdrawals
A total of 47 infants (29 %) withdrew, 23 before and 24
after initiation of the intervention (Fig. 2). The primary
reason for withdrawal after the intervention was a move
away from Dhaka (58 %), followed by the family was too
busy (13 %), and the family perceived no benefit from
study (13 %). Families in the control arm withdrew more
frequently (40 %) than the biweekly (28 %), weekly
(28 %), or daily arms (23 %); they also withdrew sooner.
Within the lowest household income group (<$100 per
month), 70 % in the control arm withdrew, compared
to 40 %, 31 %, and 14 % in the biweekly, weekly and
daily arms respectively (p = 0.04). At baseline 156 in-
fants were being breastfed, three were already weaned,
and one withdrew before any baseline information was
collected.
Safety
Cough and congestion were the most commonly re-
ported symptoms (median 12 % and 14 % of follow-up
days, respectively). Gastrointestinal symptoms were rare
(Table 2). No differences were observed in percentage of
follow-up time with diarrhea, watery or soft stool, vomit-
ing, poor feeding, colic, cough, congestion, or difficulty
breathing across arms (Table 2). Seventy percent of in-
fants were being exclusive breastfed at eight weeks of
age, while only 30 % were being exclusively breastfed at
twenty weeks of age. No differences in exclusive breast-
feeding rates were seen among study arms throughout
the study. Eight infants (four from the biweekly arm,
two from the weekly arm, two from the daily arm, and
zero from the control arm) were hospitalized a total of
ten times—six for pneumonia and four for diarrhea; all
infants recovered fully. No hospitalization was tempor-
ally related to probiotic use or considered probiotic-
related by the DSMB. Three infants had been weaned
before enrollment; all three were hospitalized (50 % of
hospitalizations). No allergic responses or other reac-
tions were observed after probiotic administration.
Table 1 Baseline characteristics of the study population
Characteristic Control (n = 32) Biweekly (n = 35) Weekly (n = 35) Daily (n = 35)
Age in weeks [mean (SD)] 7.7 (2.3) 8.1 (2.0) 8.3 (2.0) 8.2 (2.3)
Female infant [n, (%)] 18 (56) 16 (46) 16 (46) 18 (51)
Born by cesarean section [n (%)] 11 (34) 6 (17) 8 (23) 9 (26)
Previous antibiotic use [n (%)] 5 (17) 11 (31) 10 (31) 8 (24)
Bowel movements in past 24 h [mean (SD)] 2.25 (1.8) 2.7 (2.0) 2.5 (1.6) 3.2 (2.6)
Years of maternal education (formal schooling) [mean (SD)] 5.3 (3.0) 5.5 (3.2) 4.7 (3.3) 4.6 (2.6)
Household size [mean (SD)] 4.7 (1.6) 4.7 (1.8) 4.3 (1.3) 4.5 (2.0)
Household monthly income [n, (%)]
<$100 7 (22) 5 (14) 14 (40) 14 (40)
$100-$150 16 (50) 11 (31) 11 (31) 10 (29)
>$150 9 (28) 19 (54) 10 (29) 11 (31)
Table 2 Median percent of follow-up time with symptoms per infant
Symptom [Median (SD)] Control n = 32 Biweekly n = 35 Weekly n = 35 Dailyn = 35 p-value p-for trend
Diarrhea 0 (2.2) 0 (2.2) 0 (0.5) 0 (1.5) 0.7 0.9
Watery or soft stool 0 (3.8) 0 (7.3) 1.1 (5.5) 1.0 (5.6) 0.3 0.3
Vomiting 0 (3.2) 0 (4.8) 0 (2.9) 0 (2.8) 0.4 0.8
Poor feeding 0 (4.1) 3.3 (8.4) 1.1 (6.6) 2.1 (4.0) 0.8 0.5
Colic 0 (9.0) 0 (6.7) 1.1 (3.0) 1.1 (3.9) 0.5 0.4
Cough 10.0 (17.1) 12.3 (17.1) 14.2 (14.8) 12.8 (12.7) 0.5 0.7
Congestion 9.1 (18.2) 14.8 (17.2) 13.6 (13.0) 15.7 (11.1) 0.4 1.0
Difficulty breathing 0 (4.1) 0 (5.6) 0 (4.5) 0 (1.2) 0.2 0.3
Kruskal-Wallis Test, Test for Linear Trend
Significance for p-values was set at 0.05
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Perception of probiotics
When caretakers in the intervention arms were asked
about probiotics, 48 % reported the probiotics improved
the health of the baby, 6 % reported no benefit, and
46 % were undecided. This finding was similar across
intervention arms (p = 0.54).
Discussion
In this study, it was found that two probiotics were
safe – did not cause sudden reactions, increase symp-
tom rates, or diminish breastfeeding rates – and ac-
ceptable in infants younger than six months of age.
No problems administering the probiotics were identi-
fied, with infants able to suck and swallow the formu-
lations without difficulty or aversion. No differences
in rates of any reported symptoms were observed
among arms; additionally, no sudden adverse or allergic
reactions were found after probiotic administration, and
no hospitalizations were deemed related to probiotics
administration.
The World Health Organization and Bangladeshi pub-
lic health authorities strongly recommend exclusive
breast-feeding for the first six-months of life to promote
optimal growth, development, and health, and reduce
infant mortality from common childhood diseases
such as diarrhea and pneumonia [30]. Thus, it is im-
portant to ensure that oral administration of probio-
tics to infants did not negatively affect breastfeeding
rates. No evidence was found that oral administration
of probiotics decreased breastfeeding, preserving this
important health practice.
There had been concern that underlying dysbiosis or
impaired intestinal integrity might render infants suscep-
tible to microbial translocation of the gut and infection
by probiotic strains [31–33]. In this study no evidence of
infection by probiotic strains was found; no illnesses
were attributable to the probiotics. Although two investi-
gations of probiotics in children in Bangladesh previ-
ously demonstrated safety, the children studied were
older than those of our research [34, 35]. However, early
gut microbiome assembly may be important in prevent-
ing dysbiosis; thus, testing probiotics in younger infants
was imperative [36–40].
There have been some studies that suggest multistrain
or multispecies probiotics may improve colonization or
efficacy over monostrain probiotics [41, 42]; therefore,
two probiotics were selected to test in combination in
this study. While the selected probiotics have been well-
studied for safety and efficacy in other situations, we
cannot say that this choice of probiotics is optimal for
infant health in Bangladesh. We are currently assessing
duration of infant colonization and any physiologic sig-
nal of benefit in anticipation of a larger phase II-III trial.
Other limitations of this study include a dropout rate of
29 % and the lack of blinding in the control arm,
although this is not imperative in a phase I trial.
Conclusions
In conclusion, this study found that a L. reuteri DSM
17938 and B. longum subspecies infantis 35624 combin-
ation, even given daily, is safe and well-tolerated in very
young infants in Bangladesh. The confirmation of safety
and acceptability of these probiotics in this study popu-
lation lays the groundwork for investigation of the effi-
cacy of these probiotics in improving the health of
Bangladeshi infants.
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